Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL599958 | 0.99 | PTGS2 (0.35) | PTGS2PTGS1TAAR1GAAHSD17B10 | |
| SCHEMBL478439 | 0.93 | TAAR1 (0.36) | PTGS2PTGS1TAAR1GAAHSD17B10 | |
| SCHEMBL29488092 | 0.93 | TAAR1 (0.36) | PTGS2PTGS1TAAR1GAAHSD17B10 | |
| SCHEMBL516227 | 0.93 | TAAR1 (0.36) | PTGS2PTGS1TAAR1GAAHSD17B10 | |
| SCHEMBL29790344 | 0.93 | TAAR1 (0.36) | PTGS2PTGS1TAAR1GAAHSD17B10 | |
| SCHEMBL1648239 | 0.91 | GAA (0.36) | PTGS2PTGS1TAAR1GAAHSD17B10 | |
| SCHEMBL18044479 | 0.90 | PTGS2 (0.40) | PTGS2PTGS1TAAR1GAAHSD17B10 | |
| SCHEMBL28404512 | 0.90 | PTGS2 (0.40) | PTGS2PTGS1TAAR1GAAHSD17B10 | |
| SCHEMBL27206706 | 0.90 | PTGS2 (0.40) | PTGS2PTGS1TAAR1GAAHSD17B10 | |
| SCHEMBL17022397 | 0.90 | PTGS2 (0.40) | PTGS2PTGS1TAAR1GAAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247558-B2 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | LILLY CO ELI (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-2247558-B1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | LILLY CO ELI (US) | 2022-02-02 | — | — | EP | disclosed |
| US-20170160287-A1 | USE OF 7-CHLORO-N,N,5-TRIMETHYL-4-OXO-3-PHENYL-3,5-DIHYDRO-4H-PYRIDAZINO[4,5-B] INDOLE-1-ACETAMIDE AS A BIOMARKER OF PERIPHERAL BENZODIAZEPINE RECEPTOR LEVELS | SANOFI (FR) | 2017-06-08 | — | — | US | disclosed |
| EP-2852572-A1 | CARBOLINE AND CARBAZOLE BASED IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | Eli Lilly and Company (US) | 2015-04-01 | — | — | EP | disclosed |
| US-20150030540-A1 | Imaging agents for detecting neurological dysfunction | LILLY CO ELI (US) | 2015-01-29 | — | — | US | disclosed |
| EP-2349352-B1 | Use of 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide as a biomarker of peripheral benzodiazepine receptor levels | SANOFI SA (FR) | 2013-12-25 | — | — | EP | disclosed |
| WO-2013176698-A1 | CARBOLINE AND CARBAZOLE BASED IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | ELI LILLY AND COMPANY (US) | 2013-11-28 | — | — | WO | disclosed |
| EP-2599763-A1 | Novel imaging agents for detecting neurological dysfunction | Siemens Molecular Imaging, Inc. (US) | 2013-06-05 | — | — | EP | disclosed |
| US-8318132-B2 | Imaging agents for detecting neurological dysfunction | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120039816-A1 | USE OF 7-CHLORO-N,N,5-TRIMETHYL-4-OXO-3-PHENYL-3,5-DIHYDRO-4H-PYRIDAZINO[4,5-B] INDOLE-1-ACETAMIDE AS A BIOMARKER OF PERIPHERAL BENZODIAZEPINE RECEPTOR LEVELS | SANOFI-AVENTIS (FR) | 2012-02-16 | — | — | US | disclosed |
| US-20110091382-A1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | SIEMENS MEDICAL SOLUTION USA, INC. | 2011-04-21 | — | — | US | disclosed |
| US-20110046378-A1 | Novel Imaging Agents for Detecting Neurological Dysfunction | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| EP-2247558-A1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | Siemens Medical Solutions USA, Inc. (US) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009102498-A1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110091382-A1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | FABP7, TSPO, SLC18A3 | PTGS2 4331/4885PTGS1 4001/4885TAAR1 1605/4885 |
| US-20110046378-A1 | Novel Imaging Agents for Detecting Neurological Dysfunction | FABP7, SLC18A3, TSPO | PTGS2 4341/4885PTGS1 4034/4885TAAR1 1599/4885 |
| US-20150030540-A1 | Imaging agents for detecting neurological dysfunction | SLC18A3, TSPO, CHAT | PTGS2 4262/4885PTGS1 3846/4885TAAR1 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.